Lung Cancer
Conditions
Brief summary
The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are: * Does adding an SGLT2 inhibitor to standard cancer treatment improve survival? * Does it cause more or fewer cardiovascular toxicity? * What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works. Participants will: * Be adults diagnosed with advanced lung cancer and type 2 diabetes. * Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment. * Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies
Interventions
DRUGSGLT-2 inhibitor
SGLT2 inhibitors used for patients with lung cancer and diabetes
OTHERSham (No Treatment)
SGLT2 inhibitors are not used for patients with lung cancer and diabetes
Sponsors
Shanghai Chest Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Lung cancer patients receiving standard anti-tumor treatment; type 2 diabetes; patients with a score of 0-2 assessed by Eastern Cooperative Oncology Group's performance status; the patients agreed to participate in this study.
Exclusion criteria
* Severe abnormalities in liver, kidney or heart functions; expected lifespan less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with death | From enrollment to the end of treatment at 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with new-onset atrial fibrillation/flutter, acute coronary syndrome, myocarditis, massive pericardial effusion, heart failure and third-degree atrioventricular block. | From enrollment to the end of treatment at 12 months |
Contacts
Primary ContactJindong Chen
Outcome results
None listed